Increasing outsourcing services
in biopharmaceutical industry is expected to fuel the growth of
biopharmaceutical contract manufacturing market
Key players operating in the
market are focusing on facility expansion in order to increase their
geographical presence in the Biopharmaceutical
Contract Manufacturing market. In January 2020, Celltrion Group, a
biopharmaceutical company plans to build biopharmaceutical plant in China. The
new plant is focusing on to carry out large scale contract manufacturing
organization for the Chinese market with a plant capacity of 120,000 liters,
which will be the largest biopharmaceutical plant in the China.
Moreover, increasing adoption of
inorganic growth strategies such as merger and acquisition by key players
operating in the market is expected to drive market growth over the forecast
period. In January 2020, Cognate BioServices, a contract development and
manufacturing organization (CDMO) specialized in cell and cell-mediated gene
therapy products has acquired the Cobra Biologics, a CDMO specialized in
providing development and manufacturing services for plasmid DNA and viral
vector. With this acquisition Cognate BioServices deliver drug development and
manufacturing solutions to the cell and gene immunotherapy and regenerative
medicine industry around the world.
Contract manufacturing
organizations (CMOs) provide wide range of manufacturing services, which
include contract packaging, quality testing, and development service to
pharmaceutical and biotechnology industries. Biopharmaceutical companies prefer
CMOs due to complexity in manufacturing process of biomolecules, as they
consists of different shape, size, and behavior with significantly complex
process than pharmaceutical drugs. Contract manufacturing organizations provide
services from development of biologics to commercial scale production. Few
companies also provide cell line development, fermentation, process
optimization, and analytical characterization. Improved efficiency, weak
product pipeline, and increasing price pressure is expected to favor the growth
of biopharmaceutical contract manufacturing market in near future.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1077
In August 2019, Patheon merged
with Royal DSM to form private company DPx, a Contract Manufacturing
Organization (CMO). The new company comprises of three businesses - fine
chemicals and API production, pharmaceutical services including contract
manufacturing and proprietary products and technologies falling under the
banner of life sciences acquired by Patheon in October 2012.
Furthermore, key players
operating in the market are focusing on strategic partnership for expanding its
contract manufacturing facility. For instance in January 2020, Indapta
Therapeutics and Lonza, a biopharmaceutical company announced a strategic
partnership to advance a next-generation, off-the-shelf, allogeneic
immuno-oncology therapy. Under the terms of this partnership, Lonza will
manufacture Indapta’s off-the-shelf, allogeneic G-NK cell therapy under current
good manufacturing practices (cGMP) for use in clinical studies. Similarly,
Indapta will leverage Lonza’s process development capabilities and expertise to
ensure a robust, reproducible and scalable cGMP process. Process development
and manufacturing will take place in Lonza's state-of-the-art cell and gene
therapy manufacturing facility in Houston (TX), USA.
Reducing cost and focusing on
core strengths is expected to fuel the growth of biopharmaceutical contract
manufacturing market
Companies operating in the global
market are focusing on technological advancement such as use of Artificial
Intelligence in biologics manufacturing is anticipated to propel the market
growth over the forecast period. For instance in January 2020, iBioPharma Inc.,
a biotechnology company entered into collaboration EdgePoint AI, a division of
Mateon Therapeutics to use EdgePoint’s proprietary artificial intelligence
(AI)/blockchain-driven vision system for pharmaceutical manufacturing which
known as TrustPoint Fabric.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/biopharmaceutical-contract-manufacturing-market-1077
It provides highest level of
compliance to the pharmaceutical industry’s standards for data integrity and
enhanced automation capabilities which are expected to lower operating costs
while improving quality for clients of iBio’s biologics contract development
and manufacturing services.
Besides, existing companies are
investing to increase its manufacturing capabilities. In October 2019,
Mesoblast, an Australian-based regenerative medicine company and Lonza entered
into an agreement for commercial manufacturing of Mesoblast’s allogeneic
(off-the-shelf) cell therapy product candidate, remestemcel-L. The agreement
enables Lonza to expand its Singapore cGMP facilities and also anticipates to
introduce new technologies and process improvements which are expected to
result in significant increase in its manufacturing yields and efficiencies.
The key players in operating in
the global biopharmaceutical contract manufacturing market include Lonza Group
Ltd., ProBioGen AG, Boehringher Ingelheim, BIOMEVA GmbH, Celonic GmbH, Sandoz,
Fujifilm Diosynth Biotechnology, and Rentschler Biotechnologie.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1077
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment